



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 841 396 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

13.05.1998 Bulletin 1998/20

(51) Int Cl.:

C12N 15/54, C12N 9/12,
C12Q 1/68, C12Q 1/48,
C12N 15/11, C12N 15/85,
A01K 67/027, C07K 16/40,
A61K 38/45, A61K 31/70,
C12N 1/21, C12N 1/19

(21)

Application number: 97307757.1

(22) Date of filing: 01.10.1997

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LU MC
NL PT SE

Designated Extension States:

AL LT LY RO SI

(30) Priority: 01.10.1996 US 724543

18.04.1997 US 844419
25.04.1997 US 846017
06.05.1997 US 851843
09.05.1997 US 854050
14.08.1997 US 911312
14.08.1997 US 912951
14.08.1997 US 915503

(83) Declaration under Rule 28(4) EPC (expert solution)

(71) Applicants:

- Geron Corporation
Menlo Park, CA 94025 (US)
- University Technology Corporation
Boulder, CO 80301 (US)

(72) Inventors:

- Cech, Thomas R.
Boulder Colorado 80303 (US)
- Lingner, Joachim
Boulder Colorado 80303 (US)

(54) Human telomerase catalytic subunit

(57) The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention

- Nakamura, Toru
Boulder Colorado 80303 (US)
- Chapman, Karen B.
Sausalito California 94965 (US)
- Morin, Gregg B.
Palo Alto California 94303 (US)
- Harley, Calvin
Palo Alto California 94301 (US)
- Andrews, William H.
Richmond California 94885 (US)

(74) Representative: Blizley, Richard Edward et al
Hepworth, Lawrence, Bryer & Blizley
Merlin House
Falconry Court
Baker's Lane
Epping Essex CM16 5DQ (GB)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.
A request for correction of page 33 in the Accession number at line 13 and for substitution of page 274 has been filed pursuant to Rule 88 EPC. A decision on the request will be taken during the proceedings before the Examining Division (Guidelines for Examination in the EPO, A-V, 3.).

tion are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

EP 0 841 396 A1